EUZ — Eckert & Ziegler SE Share News
0.000.00%
Last trade - 00:00- €770.94m
- €703.00m
- €311.96m
Brief: Eckert & Ziegler Signs Agreement For The Supply Of Lutetium-177 With Point Biopharma
Brief: Eckert & Ziegler Collaborates With RefleXion Medical And Telix Pharmaceuticals On Treatment For Prostate Cancer
Brief: Eckert & Ziegler Forecast For 2023 Remains Unchanged
Brief: Eckert & Ziegler Preliminary H1 Profit Down, Outlook Confirmed
Brief: Eckert & Ziegler Pentixapharm Receives Bfarm-Clearance For Its Therapeutic To Conduct A Clinical Trial In Lymphoma
Brief: Eckert & Ziegler: Australian Endocrine & Hypertension Center Joins Clinical Trial Of PentixaPharm
Brief: Eckert & Ziegler Reports Q1 Sales EUR 58 Million; Guidance Unchanged
Brief: Eckert & Ziegler Receives Environmental Approval For Jintan Radioisotope Site
Brief: Eckert & Ziegler To Supply Point Biopharma With Actinium-225
Brief: Eckert & Ziegler Sees 2023 Net Profit At Around EUR 25 Mln
Brief: Eckert & Ziegler Plans Change Of Legal Form To European Stock Corporation (SE)
Brief: Eckert & Ziegler Says It Closed FY 2022 With Sales Of 222.3 Million EUR
Brief: Eckert & Ziegler Submits Drug Master File For Lu-177 N.C.A.
Brief: Eckert & Ziegler Sees 2022 Net Profit Up At EUR 30 Mln
Brief: Eckert & Ziegler Acquires All Shares In Myelo Therapeutics Gmbh
Eckert & Ziegler CEO to transfer to supervisory board
Brief: Eckert & Ziegler CEO To Transfer To Supervisory Board
Eckert & Ziegler drops on report of share placement
Eckert & Ziegler dives on report of capital increase